Cargando…

Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges

Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CH...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kexin, Xiao, Kunmin, Zhu, Shijie, Wang, Yong, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117702/
https://www.ncbi.nlm.nih.gov/pubmed/35600861
http://dx.doi.org/10.3389/fphar.2022.889799
_version_ 1784710367741476864
author Li, Kexin
Xiao, Kunmin
Zhu, Shijie
Wang, Yong
Wang, Wei
author_facet Li, Kexin
Xiao, Kunmin
Zhu, Shijie
Wang, Yong
Wang, Wei
author_sort Li, Kexin
collection PubMed
description Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC. Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations. Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed. Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed. Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC.
format Online
Article
Text
id pubmed-9117702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91177022022-05-20 Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges Li, Kexin Xiao, Kunmin Zhu, Shijie Wang, Yong Wang, Wei Front Pharmacol Pharmacology Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC. Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations. Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed. Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed. Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC. Frontiers Media S.A. 2022-05-05 /pmc/articles/PMC9117702/ /pubmed/35600861 http://dx.doi.org/10.3389/fphar.2022.889799 Text en Copyright © 2022 Li, Xiao, Zhu, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Kexin
Xiao, Kunmin
Zhu, Shijie
Wang, Yong
Wang, Wei
Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title_full Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title_fullStr Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title_full_unstemmed Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title_short Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
title_sort chinese herbal medicine for primary liver cancer therapy: perspectives and challenges
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117702/
https://www.ncbi.nlm.nih.gov/pubmed/35600861
http://dx.doi.org/10.3389/fphar.2022.889799
work_keys_str_mv AT likexin chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges
AT xiaokunmin chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges
AT zhushijie chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges
AT wangyong chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges
AT wangwei chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges